myeloproliferative


Also found in: Dictionary, Wikipedia.

myeloproliferative

 [mi″ĕ-lo-pro-lif´er-ah″tiv]
pertaining to or characterized by abnormal proliferation of bone marrow constituents.
myeloproliferative disorders a group of usually neoplastic diseases, which may be related histogenetically by a common multipotential stem cell; it includes among others acute myelogenous leukemia, chronic granulocytic leukemia, acute and chronic myelomonocytic leukemias, and polycythemia vera. An interrelationship with the lymphoproliferative disorders is thought to exist.

my·e·lo·pro·lif·er·a·tive

(mī'ĕ-lō-prō-lif'ĕr-ă-tiv),
Pertaining to or characterized by unusual proliferation of myelopoietic tissue.

myeloproliferative

(mī′ə-lō-prə-lĭf′ə-rā′tĭv, -lĭf′ə-rə-tĭv)
adj.
Relating to excess proliferation of hematopoietic stem cells, chiefly in the bone marrow, as in chronic myelogenous leukemia and polycythemia vera.

myeloproliferative

(mī′ə-lō-prə-lĭf′ə-rā′tĭv, -ər-ə-tĭv)
adj.
Relating to or characterized by the proliferation of cells of the bone marrow: myeloproliferative disorders.

my·e·lo·pro·lif·er·a·tive

(mī'ĕ-lō-prō-lif'ĕr-ă-tiv)
Pertaining to or characterized by unusual proliferation of myelopoietic tissue.
References in periodicals archive ?
Similarly to ITP, ET is also a diagnosis of exclusion once other thrombocytoses such as reactive thrombocytosis, myelodysplastic syndrome (MDS), and other myeloproliferative neoplasms (MPN) have been eliminated.
Myeloproliferative Neoplasmas in Rodak's Hematology.
BIOMARKER REPORTING TEMPLATE Myeloproliferative Neoplasms (MPNs) Select a single response unless otherwise indicated.
Neutrophils with ring-shaped nuclei in myeloproliferative disease.
(13) (1/145) (19/113) aCML: atypical chronic myeloid leukemia; CMML: chronic myelomonocytic leukemia; MDS: myelodysplastic syndrome; MPN: myeloproliferative neoplasm; MDS-MPN, U: myelodysplastic-myeloproliferative neoplasm, unclassifiable; JMML: juvenile myelomono-cytic leukemia; PMF: primary myelofibrosis; CNL: chronic neutrophilic leukemia; AML: acute myeloid leukemia; sAML: secondary acute myeloid leukemia; ND: no data.
To date, the promising approaches designed for patients with chronic myelogenous leukemia or other myeloproliferative neoplasms, has not been achieved in patients with EMS.
Beer et al., "Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation," Blood, vol.
Myeloproliferative neoplasms (MPNs) consist of various clonal hematological diseases that are considered to develop from the hematopoietic stem cell transformation.
Although JAK2 and MPL mutations are not supposed to be primary causes of MPN, but rather secondary events associated with disease progression in a still unknown way, the acquisition of one of these gain-of-function mutations seems to be necessary for the development of the myeloproliferative phenotype.
'Patients also showed a reduction in their myeloproliferative neoplasm symptoms, as well as a trend to prolonged survival with PRM-151 monotherapy in these refractory MF patients with great unmet need.'
The patient was evaluated by hematology-oncology, and no underlying myeloproliferative or dysplastic disease was found.
Additionally, data to be presented at EHA will showcase the continued study of Incyte's JAK1/JAK2 inhibitor, ruxolitinib, in myeloproliferative neoplasms.